{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:18:39Z","timestamp":1790857119759,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A major unmet clinical need is a therapeutic capable of removing hepatitis B virus (HBV) genome from the liver of infected individuals to reduce their risk of developing liver cancer. A strategy to deliver such a therapy could utilize the ability to target and promote apoptosis of infected hepatocytes. Presently there is no clinically relevant strategy that has been shown to effectively remove persistent episomal covalently closed circular HBV DNA (cccDNA) from the nucleus of hepatocytes. We used linearized single genome length HBV DNA of various genotypes to establish a cccDNA-like reservoir in immunocompetent mice and showed that clinical-stage orally administered drugs that antagonize the function of cellular inhibitor of apoptosis proteins can eliminate HBV replication and episomal HBV genome in the liver. Primary human liver organoid models were used to confirm the clinical relevance of these results. This study underscores a clinically tenable strategy for the potential elimination of chronic HBV reservoirs in patients.<\/jats:p>","DOI":"10.1038\/s41419-021-03924-0","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:06:11Z","timestamp":1624442771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-3655","authenticated-orcid":false,"given":"Michelle P.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2658-1846","authenticated-orcid":false,"given":"Thao","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shringar","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Mackiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Romal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Stutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang H.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Earnest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitina","family":"Sozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-2664","authenticated-orcid":false,"given":"Margaret","family":"Littlejohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3108-8805","authenticated-orcid":false,"given":"Bang M.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Vincan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Torresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Netter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokameh","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Revill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5318-3037","authenticated-orcid":false,"given":"Gregor","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"3924_CR1","unstructured":"World Health Organization. WHO global hepatitis report 2017. World Health Organization; 2017. p. 1\u201383. Avaliable from: https:\/\/apps.who.int\/iris\/handle\/10665\/255016."},{"key":"3924_CR2","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","volume":"126","author":"B Werle-Lapostolle","year":"2004","unstructured":"Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750\u20138.","journal-title":"Gastroenterology"},{"key":"3924_CR3","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","volume":"64","author":"D Durantel","year":"2016","unstructured":"Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64:S117\u2013S131.","journal-title":"J Hepatol"},{"key":"3924_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrgastro.2017.44","volume":"14","author":"U Protzer","year":"2017","unstructured":"Protzer U. Viral hepatitis: The bumpy road to animal models for HBV infection. Nat Rev Gastroenterol Hepatol. 2017;14:327\u20138.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3924_CR5","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Xu G, He W, Jing Z, Gaon Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife. 2012;1:e00049.","journal-title":"elife"},{"key":"3924_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.bpg.2017.04.014","volume":"31","author":"M Dandri","year":"2017","unstructured":"Dandri M, Petersen J. Animal models of HBV infection. Best Pract Res Clin Gastroenterol. 2017;31:273\u20139.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"3924_CR7","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.1128\/JVI.03134-12","volume":"87","author":"S Dion","year":"2013","unstructured":"Dion S, Bourgine M, Godon O, Levillayer F, Michel ML. Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J Virol. 2013;87:5554\u201363.","journal-title":"J Virol"},{"key":"3924_CR8","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1128\/JVI.75.11.5108-5118.2001","volume":"75","author":"MF Sprinzl","year":"2001","unstructured":"Sprinzl MF, Oberwinkler H, Schaller H, Protzer U. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. J Virol. 2001;75:5108\u201318.","journal-title":"J Virol"},{"key":"3924_CR9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1053\/j.gastro.2012.03.006","volume":"142","author":"LR Huang","year":"2012","unstructured":"Huang LR, G\u00e4bel YA, Graf S, Arzberger A, Kurts C, Heikenwalder M, et al. Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. Gastroenterology. 2012;142:1447. e3","journal-title":"Gastroenterology"},{"key":"3924_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.antiviral.2017.07.006","volume":"145","author":"J Lucifora","year":"2017","unstructured":"Lucifora J, Salvetti A, Marniquet X, Mailly L, Testoni B, Fusil F, et al. Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antivir Res. 2017;145:14\u201319.","journal-title":"Antivir Res"},{"key":"3924_CR11","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1073\/pnas.1502390112","volume":"112","author":"G Ebert","year":"2015","unstructured":"Ebert G, Preston S, Allison C, Cooney J, Toe JG, Stutz MD, et al. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc Natl Acad Sci USA. 2015;112:5797\u2013802.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3924_CR12","doi-asserted-by":"publisher","first-page":"17862","DOI":"10.1073\/pnas.0608578103","volume":"103","author":"LR Huang","year":"2006","unstructured":"Huang LR, Wu HL, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA. 2006;103:17862\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3924_CR13","doi-asserted-by":"publisher","first-page":"13825","DOI":"10.1073\/pnas.202398599","volume":"99","author":"PL Yang","year":"2002","unstructured":"Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA. 2002;99:13825\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3924_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep25552","volume":"6","author":"X Guo","year":"2016","unstructured":"Guo X, Chen P, Hou X, Xu W, Wang D, Wang TY, et al. The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely. Sci Rep. 2016;6:25552.","journal-title":"Sci Rep"},{"key":"3924_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jhep.2017.02.004","volume":"66","author":"Z Yan","year":"2017","unstructured":"Yan Z, Zeng J, Yu Y, Xiang K, Hu H, Zhou X, et al. HBVcircle: a novel tool to investigate hepatitis B virus covalently closed circular DNA. J Hepatol. 2017;66:1149\u201357.","journal-title":"J Hepatol"},{"key":"3924_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1128\/JCM.36.2.531-538.1998","volume":"36","author":"S G\u00fcnther","year":"1998","unstructured":"G\u00fcnther S, Sommer G, von Breunig F, Iwanska A, Kalinina T, Sterneck M, et al. Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. J Clin Microbiol. 1998;36:531\u20138.","journal-title":"J Clin Microbiol"},{"key":"3924_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cell.2014.11.050","volume":"15","author":"M Huch","year":"2015","unstructured":"Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MMA, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015;15:299\u2013312.","journal-title":"Cell"},{"key":"3924_CR18","unstructured":"De Crignis E, Carofiglio F, Moulos P, Verstegen MMA, Romal S, Khalid MM, et al. Human liver organoids; a patient-derived primary model for HBV infection and related hepatocellular carcinoma. 2010. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/568147v2."},{"key":"3924_CR19","first-page":"839","volume":"8","author":"DJ Flanagan","year":"2016","unstructured":"Flanagan DJ, Schwab RHM, Tran BM, Phesse TJ, Vincan E. Isolation and culture of adult intestinal, gastric, and liver organoids for cre-recombinase-mediated gene deletion. Methods Mol Biol. 2016;8:839\u201311.","journal-title":"Methods Mol Biol"},{"key":"3924_CR20","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1073\/pnas.1502400112","volume":"112","author":"G Ebert","year":"2015","unstructured":"Ebert G, Allison C, Preston S, Cooney J, Toe JG, Stutz MD, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci USA. 2015;112:5803\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3924_CR21","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1016\/j.celrep.2020.03.032","volume":"30","author":"G Ebert","year":"2020","unstructured":"Ebert G, Lopaticki S, O\u2019Neill MT, Steel RWJ, Doerflinger M, Rajasekaran P, et al. Targeting the extrinsic pathway of hepatocyte apoptosis promotes clearance of plasmodium liver infection. Cell Rep. 2020;30:4343. e4","journal-title":"Cell Rep"},{"key":"3924_CR22","first-page":"287","volume":"6","author":"DL Vaux","year":"2005","unstructured":"Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Publ Group. 2005;6:287\u201397.","journal-title":"Nat Publ Group"},{"key":"3924_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2008.05.014","volume":"30","author":"MJM Bertrand","year":"2008","unstructured":"Bertrand MJM, Miltutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30:689\u2013700.","journal-title":"Mol Cell"},{"key":"3924_CR24","doi-asserted-by":"publisher","first-page":"11778","DOI":"10.1073\/pnas.0711122105","volume":"105","author":"DJ Mahoney","year":"2008","unstructured":"Mahoney DJ, Cheung HH, Lejmi Mrad R, Plenchette S, Simard C, Enwere E, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA. 2008;105:11778\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3924_CR25","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.12688\/f1000research.16439.1","volume":"7","author":"N Lalaoui","year":"2018","unstructured":"Lalaoui N, Vaux DL. Recent advances in understanding inhibitor of apoptosis proteins. F1000Res. 2018;7:1889.","journal-title":"F1000Res"},{"key":"3924_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2014.05.007","volume":"144","author":"L Bai","year":"2014","unstructured":"Bai L, Smith DC, Wang S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharm Ther. 2014;144:82\u201395.","journal-title":"Pharm Ther"},{"key":"3924_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2007.10.037","volume":"131","author":"JE Vince","year":"2007","unstructured":"Vince JE, Wong WWL, Khan N, Feltham R, Chau D, Ahmen AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131:682\u201393.","journal-title":"Cell"},{"key":"3924_CR28","doi-asserted-by":"publisher","first-page":"10054","DOI":"10.1128\/JVI.01293-16","volume":"90","author":"V Sozzi","year":"2016","unstructured":"Sozzi V, Walsh R, Littlejohn M, Colledge D, Jackson K, Warner N, et al. In vitro studies show that sequence variability contributes to marked variation in hepatitis B virus replication, protein expression, and function observed across genotypes. J Virol. 2016;90:10054\u201364.","journal-title":"J Virol"},{"key":"3924_CR29","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1128\/jvi.69.9.5437-5444.1995","volume":"69","author":"S G\u00fcnther","year":"1995","unstructured":"G\u00fcnther S, Li BC, Miska S, Kr\u00fcger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol. 1995;69:5437\u201344.","journal-title":"J Virol"},{"key":"3924_CR30","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1084\/jem.184.4.1397","volume":"184","author":"M Pasparakis","year":"1996","unstructured":"Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory response in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune responses. J Exp Med. 1996;184:1397\u2013411.","journal-title":"J Exp Med"},{"key":"3924_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-3581-9_9","volume":"1419","author":"SP Preston","year":"2016","unstructured":"Preston SP, Pellegrini M, Ebert G. Hydrodynamic injection as a method of gene delivery in mice: a model of chronic Hepatitis B virus infection. Methods Mol Biol. 2016;1419:109\u201315.","journal-title":"Methods Mol Biol"},{"key":"3924_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.virol.2010.12.034","volume":"411","author":"R Walsh","year":"2011","unstructured":"Walsh R, Nuttall S, Revill P, Colledge D, Cabuang L, Soppe S, et al. Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virology. 2011;411:132\u201341.","journal-title":"Virology"},{"key":"3924_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature11826","volume":"494","author":"M Huch","year":"2013","unstructured":"Huch M, Dorrell C, Boj SF, van Es JH, Li VSW, van de Wetering M, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature. 2013;494:247\u201350.","journal-title":"Nature"},{"key":"3924_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.stem.2009.11.013","volume":"6","author":"N Barker","year":"2010","unstructured":"Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell. 2010;6:25\u201336.","journal-title":"Cell Stem Cell"},{"key":"3924_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0022-2836(67)90307-5","volume":"26","author":"B Hirt","year":"1967","unstructured":"Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol. 1967;26:365\u20139.","journal-title":"J Mol Biol"},{"key":"3924_CR36","first-page":"187.","volume":"91","author":"J Luo","year":"2017","unstructured":"Luo J, Cui X, Gao L, Hu J. Identification of an intermediate in hepatitis B virus covalently closed circular (CCC) DNA formation and sensitive and selective CCC DNA detection. J Virol. 2017;91:187.","journal-title":"J Virol"},{"key":"3924_CR37","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","volume":"41","author":"SK Ladner","year":"1997","unstructured":"Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997;41:1715\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"3924_CR38","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1021\/jm101505d","volume":"54","author":"Q Cai","year":"2011","unstructured":"Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, et al. A potent and orally active antagonist (SM-406\/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011;54:2714\u201326.","journal-title":"J Med Chem."},{"key":"3924_CR39","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00280-015-2709-8","volume":"75","author":"HI Hurwitz","year":"2015","unstructured":"Hurwitz HI, Smith DC, Pitot HC, Brill JM, Chugh R, Rouits E, et al. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemother Pharm. 2015;75:851\u20139.","journal-title":"Cancer Chemother Pharm"},{"key":"3924_CR40","doi-asserted-by":"publisher","first-page":"C2","DOI":"10.1186\/1476-4598-14-2","volume":"14","author":"I Ray-Coquard","year":"2015","unstructured":"Ray-Coquard I, Le Tourneau C, Isambert N, Gomez-Roca CA, Cassier P, Sablin MP, et al. Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study. Abstract of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. Mol Cancer Ther. 2015;14:C2\u2013C2.","journal-title":"Mol Cancer Ther"},{"key":"3924_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm"},{"key":"3924_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.immuni.2008.10.017","volume":"30","author":"T Kauffman","year":"2009","unstructured":"Kauffman T, Jost PJ, Pellegrini M, Puthalakath H, Gugasyan R, Gerondakis S, et al. Fatal hepatitis mediated by TNF\u2212\/\u2212 requires Caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity. 2009;30:56\u201366.","journal-title":"Immunity"},{"key":"3924_CR43","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/pbc.23167","volume":"58","author":"PJ Houghton","year":"2012","unstructured":"Houghton PJ, Kang MH, Reyholds CP, Morton CL, Kolb EA, Gorlick R, et al. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012;58:636\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"3924_CR44","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1200\/JCO.2013.52.3993","volume":"32","author":"JR Infante","year":"2014","unstructured":"Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Camerson S, et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014;32:3103\u201310.","journal-title":"J Clin Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03924-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T08:58:45Z","timestamp":1669971525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03924-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["3924"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03924-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"9 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Walter and Eliza Hall Institute of Medical Research Animal Ethics Committee reviewed and approved all animal experiments (AEC Project 2017.016). Written informed consent was obtained from all patients prior to inclusion in the human organoid study. The Medical Ethical Council of the Erasmus Medical Centre (MERC) has approved the use of liver biopsies for research purposes (Project number MEC-2014-060). This includes the liver biopsies collected from healthy donors and infected patients to generate liver organoids used in this study, received through the department of Transplantation and Surgery at ErasmusMC. The MERC reviews on the basis of the Declaration of Helsinki and other relevant legislation and regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Debiopharm International SA, the manufacturer of the monovalent IAP inhibitor Debio 1143, sponsored parts of the research performed at The Walter and Eliza Hall Institute of Medical Research under a research license agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"641"}}